A Retrospective, Cross-Sectional Study on the Prevalence of Hyperuricemia Using a Japanese Healthcare Database
Shingo HIGA1, Mizuki YOSHIDA2, Daisuke SHIMA1, Yoichi II2, Shigeru KITAZAKI3, Yuji YAMAMOTO3, Yoko FUJIMOTO1
1Pfizer Japan Inc., Medical Affairs, Pfizer Essential Health, Tokyo, Japan
2Pfizer Japan Inc., Clinical Statistics, Development Japan, Tokyo, Japan
3Minacare Co., Ltd., Tokyo, Japan
Keywords: Claims data, hyperuricemia, MinaCare database, prevalence
Objectives: This study aims to evaluate the prevalence of hyperuricemia (HU) considering both serum uric acid (SUA) levels and medication status of urate-lowering drugs (ULDs), and the association between HU and its comorbidities using a Japanese healthcare database.
Materials and Methods: The study population consisted of 60,828 subjects who had at least one serum uric acid measurement between the fiscal years (FYs) 2010 and 2014 in a Japanese employment-based health insurance database (MinaCare Co., Ltd., Tokyo, Japan), which includes mutually linked medical/pharmaceutical claims data and health check-up data. Hyperuricemia was defined as a SUA level >7.0 mg/dL of the health check-up data and/or a prescription for a ULD. The association between HU and comorbidities were analyzed by comparing the prevalence of HU of each subgroup defined by presence or absence of comorbidity.
Results: The prevalence of HU in FY 2014 was 26.8% [95% confidence interval (CI): 26.2 to 27.3%] in male subjects and 0.9% (95% CI: 0.7 to 1.0%) in female subjects. According to the analyses by sex and age, a trend of increasing prevalence with age was observed in both males and females. The prevalence of HU remained stable both in males and females from FYs 2010 to 2014. The positive association between HU and well-known comorbidities were confirmed with the exception of diabetes mellitus and smoking status in male subjects.
Conclusion: Our results provided a more accurate prevalence of HU in Japanese population. It is important to increase the awareness on HU in the society to reduce the burden of HU-related diseases.
Citation: Higa S, Yoshida M, Shima D, Ii Y, Kitazaki S, Yamamoto Y, et al. A Retrospective, Cross-Sectional Study on the Prevalence of Hyperuricemia Using a Japanese Healthcare Database. Arch Rheumatol 2020;35(1):41-51.
SH, MY, DS, YI, and YF are full-time employees of Pfizer Japan Inc. YY is the founder and CEO of MinaCare Co., Ltd., and SK is full-time employee of MinaCare Co., Ltd.
This research was sponsored and funded by Pfizer.
The authors would like to thank Shin Fujimori of Teikyo University Shinjuku Clinic for his helpful advice.